Understanding the molecular mechanisms driving resistance to anti-cancer drugs is both a crucial step to define markers of response to therapy and a clinical need in many cancer settings. YAP and TAZ transcriptional cofactors behave as oncogenes in different cancer types. Deregulation of YAP/TAZ expression or alterations in components of the multiple signaling pathways converging on these factors are important mechanisms of resistance to chemotherapy, target therapy and hormone therapy. Moreover, response to immunotherapy may also be affected by YAP/TAZ activities in both tumor and microenvironment cells. For these reasons, various compounds inhibiting YAP/TAZ function by different direct and indirect mechanisms have been proposed as a mean to counter-act drug resistance in cancer. A particularly promising approach may be to simultaneously target both YAP/TAZ expression and their transcriptional activity through BET inhibitors.

中文翻译：

---

YAP和TAZ介导的抗癌治疗抗性的多种作用和特定于上下文的机制。

了解驱动抗癌药物耐药性的分子机制既是定义对治疗反应的标志物的关键步骤，也是许多癌症环境中的临床需求。YAP和TAZ转录辅助因子在不同类型的癌症中起癌基因的作用。YAP / TAZ表达的失调或聚集在这些因素上的多种信号传导途径的组成改变是对化学疗法，靶标治疗和激素治疗产生抗性的重要机制。此外，在肿瘤和微环境细胞中，对免疫疗法的反应也可能受到YAP / TAZ活性的影响。由于这些原因，已经提出了通过不同的直接和间接机制抑制YAP / TAZ功能的各种化合物作为抵抗癌症中药物抗性的手段。